Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment
Laurent Bertoletti, University Professor and Hospital Practitioner at Jean Monnet University, Saint-Etienne, shared on LinkedIn:
”Thank you to the scientific council of the French Days of Pulmonary Hypertension RespiFil for the invitation to present an update on the treatment anticoagulant in pulmonary hypertension.
It is an honour to be able to share data from the French registry and to discuss a topic that is as debated as it is crucial for patient care.
The prescription of anticoagulants now seems to be restricted to patients with a validated indication such as a history of MTEV or atrial fibrillation.
The next collective objective is to determine the best therapeutic antithrombotic strategy, in patients with PH-TEC or PH and a validated indication.”
Stay updated with Hemostasis Today.
-
Jul 4, 2026, 12:47Panagiota Tsiatsiou: Tissue Factor Biomarkers Reveal Persistent Procoagulant Activity During Combined Androgen Blockade in Prostate Cancer
-
Jul 4, 2026, 12:45Seema Dawood: Abnormal Nuclear Morphology of NeutrophilÂ
-
Jul 4, 2026, 12:34Omar Adwan: Are You Following Proper Phlebotomy Technique?
-
Jul 4, 2026, 12:24Gabriela Hobbs: Outcomes of MPN Patients with Concurrent Driver Mutations
-
Jul 4, 2026, 12:04Lara Bloom: Building Momentum for Rare Diseases
-
Jul 4, 2026, 11:52Heghine Khachatryan: A Valuable Educational Resource on Inhibitor Development
-
Jul 4, 2026, 11:42Roshni Kulkarni: Study Underscores the Urgent Need to Prevent Postpartum Hemorrhage Deaths
-
Jul 4, 2026, 11:25Michael Cahillane: Latest Transfusion Medicine Research Takes Center Stage at ISBT Congress
-
Jul 4, 2026, 11:10Henning Nilius: Career Milestone Reached with FAMH Specialist Certification